|Bid||9.93 x 800|
|Ask||10.22 x 1300|
|Day's Range||10.00 - 10.80|
|52 Week Range||10.00 - 28.26|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.00|
Foghorn Therapeutics (FHTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, announced today the appointment of Peleg Chevion as President and Chief Commercial Officer. Chevion, who joined the company in late 2020, will focus on accelerating the commercial activities of the company.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...